REFERENCES
- WarkentinTE, GreinacherA. Heparin-induced thrombocytopenia: recognition, treatment and prevention: the Seventh ACCP Con-ference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 311S–37S.
- Kelton JG. The pathophysiology of heparin-induced thrombo-cytopenia: biological basis for treatment. Chest 2005; 127: 9S–20S.
- Arepally GM, OrtelTL. Clinical practice. Heparin-induced throm-bocytopenia. N Engl J Med 2006; 355:809–17.
- Samama MM, Gerotziafas GT. Evaluation of the pharmacologi-cal properties and clinical results of the synthetic pentasac-charide (fondaparinux). Thromb Res 2003; 109:1–11.
- Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings.] Thromb Haemost 2006; 4: 759–65.
- Chong BH. Heparin-induced thrombocytopenia. J Thromb Hae-most 2003; 1: 1471–8.
- Elalamy I, Lecru bier C, Potevin F, et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated throm-bocytopenia. Thromb Haemost 1995 ; 74: 1384–5.
- Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombo-cytopenia associated with fondaparinux. N Eng1J Med 2007 ; 356: 2653–5.
- Harenberg J, Jörg I, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica 2004; 89: 1017–8.
- Kuo KHM, Kovacs M J. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 2005; 93:999–1000.
- Papadopoulos S, Flynn JD, Lewis DA. Fondaparinux as a treatment option for heparin-induced thrombocytopenia. Pharmacother-apy 2007; 27: 921–6.
- Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treat-ment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008; 99: 208–14.